Opioid-Induced Hypogonadism: Why and How to Treat It
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Gonadal hormones are critical factors in modulating the experience of pain, as suggested by the several sex differences observed: women have a greater risk of many clinical pain conditions, and postoperative and procedural pain may be more severe in them than in men. A growing body of literature demonstrates the role of estrogen in the female pain experience, whereas less attention has been given to testosterone and its functions. Nevertheless, testosterone has an appreciable role in both women and men: adequate serum levels are required in males and females for libido and sexuality; cellular growth; maintenance of muscle mass and bone; healing; blood-brain barrier; and for central nervous system maintenance. Pain therapy, and particularly opioid therapy, has been shown to affect testosterone plasma levels. Thus, the chronic administration of pain killers, such as opioids, requires the physician to be aware of both the consequences that can develop due to long-term testosterone impairment and the available means to restore and maintain physiological testosterone levels. Objective: The objective is to highlight to pain physicians that the endocrine changes occurring during chronic pain therapy can participate in the body dysfunctions often present in chronic pain patients and that there are possible hormone replacement methods that can be carried out in men and women to improve their quality of life. Study Design: A comprehensive review of the literature. Methods: A comprehensive review of the literature relating to opioid-induced hypogonadism, as well as other very common forms of hypogonadism, its endocrine effects, and possible therapeutic actions. The literature was collected from electronic and other sources. The reviewed literature included observational studies, case reports, systematic reviews, and guidelines. Outcome Measures: Evaluation of the endocrine changes described in chronic pain therapy was the primary outcome measure. The secondary outcome measures were functional improvement and adverse effects of hormone replacement. Results: The results of the survey clearly show that sex hormone determination is very rare in pain centers. Given the complexity and widespread nature of pain therapy, there is a paucity of qualitative and quantitative literature regarding its endocrine consequences. The available evidence is weak for pain relief, but is consistent for many collateral effects, possibly deriving from pain therapy, such as fatigue, depression, and neurodegenerative diseases. Limitation: This is a narrative review without application of methodological quality assessment criteria. Even so, there is a paucity of literature concerning both controlled and observational literature for the endocrine effects of most analgesic drugs. Conclusion: Testosterone replacement suffers from old prejudices about its utility and safety. With this review we illustrate the available therapeutic choices able to maintain T concentration into physiological ranges and reduce nociception with a final goal of improving patients’ quality of life. Key words: Pain, pain therapy, hypogonadism, adverse effects, morphine, HRT, testosterone
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Loss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men*
Bremner, W. J., Vitiello, M. V., & Prinz, P. N. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1278 · Cited by 785
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes
Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007) · Diabetes Care · doi:10.2337/dc06-1426 · Cited by 493
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Ferrini, R. L., & Barrett-Connor, E. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009519 · Cited by 473
Braunstein, G. D., Sundwall, D. A., Katz, M., Shifren, J. L., Buster, J. E., Simon, J. A., Bachman, G., Aguirre, O. A., Lucas, J. D., Rodenberg, C., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1582 · Cited by 458
Endogenous sex hormones in men aged 40-80 years
Muller, M., den Tonkelaar, I., Thijssen, J., Grobbee, D., & van der Schouw, Y. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490583 · Cited by 346
Diver, M. J., Imtiaz, K. E., Ahmad, A. M., Vora, J. P., & Fraser, W. D. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01772.x · Cited by 338
The impact of opioids on the endocrine system
Katz, N., & Mazer, N. A. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181850df6 · Cited by 307
Allan, C. A., Strauss, B. J. G., Burger, H. G., Forbes, E. A., & McLachlan, R. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1291 · Cited by 298
NIESCHLAG, E., SWERDLOFF, R., BEHRE, H. M., GOOREN, L. J., KAUFMAN, J. M., LEGROS, J. ‐., LUNENFELD, B., MORLEY, J. E., SCHULMAN, C., WANG, C., et al. (2005) · International Journal of Andrology · doi:10.1111/j.1365-2605.2005.00553.x · Cited by 282
Daniell, H. W. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.08.005 · Cited by 263
Brambilla, D. J., O'Donnell, A. B., Matsumoto, A. M., & McKinlay, J. B. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02976.x · Cited by 207
Hypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144
Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112
Endocrine consequences of opioid therapy
Aloisi, A. M., Aurilio, C., Bachiocco, V., Biasi, G., Fiorenzani, P., Pace, M. C., Paci, V., Pari, G., Passavanti, G., Ravaioli, L., et al. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.013 · Cited by 107
Self-citationHormone replacement therapy in morphine-induced hypogonadic male chronic pain patients
Aloisi, A., Ceccarelli, I., Carlucci, M., Suman, A., Sindaco, G., Mameli, S., Paci, V., Ravaioli, L., Passavanti, G., Bachiocco, V., et al. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-26 · Cited by 77
Self-citation
Cited by
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
Jayasena, C. N., Anderson, R. A., Llahana, S., Barth, J. H., MacKenzie, F., Wilkes, S., Smith, N., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14633 · Cited by 147
Coluzzi, F., Mattia, C., Raffa, R. R., & Pergolizzi, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79409 · Cited by 77
A novel use for testosterone to treat central sensitization of chronic pain in fibromyalgia patients
White, H. D., & Robinson, T. D. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.05.020 · Cited by 59
Valverde-Filho, J., Cunha Neto, M. B. C. D., Fonoff, E. T., Meirelles, E. D. S., & Teixeira, M. J. (2015) · Pain Medicine · doi:10.1111/pme.12661 · Cited by 37
Metadata
- Authors
- Aloisi, A. M.
- Venue
- Pain Physician
- Published
- 2012-07-14
- Volume
- 3S;15
- Issue
- 3S;7
- Pages
- ES111-ES118
- ISSN
- 1533-3159 (ISSN-L)
- 2150-1149
- OpenAlex
- W4318750794
- Cited by
- 54
- References
- 25
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.